Professor | Hao Jiang | Asia Growth Partners

Name	Hao Jiang
Contact Information	jianghao1209@csu.edu.cn
Language ability	Chinese, English
Province	Hunan

Name

Hao Jiang

Contact Information

jianghao1209@csu.edu.cn

Language ability

Chinese, English

Province

Hunan

University/Lab Affiliation and Title	Central South University
Faculty	Life Sciences
Academic Background & Achievements	2013-2017: PhD in Science, University of Chinese Academy of Sciences / East China University of Science and Technology 2010-2013: Master of Science, Northeast Normal University 2006-2010: Bachelor of Science, Northeast Normal University Hosted 1 national youth project and 2 provincial projects, received the 'Lotus Tip' talent title in Hunan
Work Experience	2017.7-2019.12 - South China University of Technology - Postdoctoral Researcher 2020.6-2023.9 - Central South University - Lecturer 2023.9-present - Central South University - Associate Professor

University/Lab Affiliation and Title

Central South University

Faculty

Life Sciences

Academic Background & Achievements

2013-2017: PhD in Science, University of Chinese Academy of Sciences / East China University of Science and Technology
2010-2013: Master of Science, Northeast Normal University
2006-2010: Bachelor of Science, Northeast Normal University
Hosted 1 national youth project and 2 provincial projects, received the 'Lotus Tip' talent title in Hunan

Work Experience

2017.7-2019.12 - South China University of Technology - Postdoctoral Researcher
2020.6-2023.9 - Central South University - Lecturer
2023.9-present - Central South University - Associate Professor

Areas of Focus	Exploration of epigenetic modifiers in tumor development and progression, discovery of precision therapeutic drugs
Publications	Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex, Hao Jiang et al., 2024 COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma, Hao Jiang et al., 2024 STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient, Hao Jiang et al., 2023 Deubiquitinase OTUD3: a double-edged sword in immunity and disease, Hao Jiang et al., 2023 Immunostimulant nanomodulator boosts antitumor immune response in triple negative breast cancer by synergism of vessel normalization and photothermal therapy, Hao Jiang et al., 2023 Identification of a CircRNA-miRNA-mRNA Network and Integrated Analysis of Immune Infiltration in Oral Squamous Cell Carcinoma, Hao Jiang et al., 2023 Fringe family genes and their modulation of Notch signaling in cancer, Hao Jiang et al., 2022 Upregulated GATA3/miR205-5p Axis Inhibits MFNG Transcription and Reduces the Malignancy of Triple-Negative Breast Cancer, Hao Jiang et al., 2022 Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis, Hao Jiang et al., 2020

Areas of Focus

Exploration of epigenetic modifiers in tumor development and progression, discovery of precision therapeutic drugs

Publications

Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex, Hao Jiang et al., 2024
COX6C expression driven by copy amplification of 8q22.2 regulates cell proliferation via mediation of mitosis by ROS-AMPK signaling in lung adenocarcinoma, Hao Jiang et al., 2024
STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient, Hao Jiang et al., 2023
Deubiquitinase OTUD3: a double-edged sword in immunity and disease, Hao Jiang et al., 2023
Immunostimulant nanomodulator boosts antitumor immune response in triple negative breast cancer by synergism of vessel normalization and photothermal therapy, Hao Jiang et al., 2023
Identification of a CircRNA-miRNA-mRNA Network and Integrated Analysis of Immune Infiltration in Oral Squamous Cell Carcinoma, Hao Jiang et al., 2023
Fringe family genes and their modulation of Notch signaling in cancer, Hao Jiang et al., 2022
Upregulated GATA3/miR205-5p Axis Inhibits MFNG Transcription and Reduces the Malignancy of Triple-Negative Breast Cancer, Hao Jiang et al., 2022
Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis, Hao Jiang et al., 2020

Epigenetics Tumor Development Tumor Progression Precision Medicine Therapeutic Drugs Clinical Treatment Cancer Research Mechanism Of Action Drug Discovery Treatment Strategies

Fang Wei - Shanghai Jiao Tong University

Andrew Teschendorff - University of Chinese Academy of Sciences

Shilai Bao - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us